GO:1990000 amyloid fibril formation: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1990000 amyloid fibril formation describes the generation of insoluble fibrous protein aggregates that exhibit a cross-beta sheet structure from soluble proteins.
• Amyloid fibril formation is a biological process relevant to both physiological functions, such as PMEL amyloid fibrils in pigmentation, and pathological conditions including Alzheimer's disease and atherosclerosis.
• The process is driven by the exposure of aggregation-prone segments, often triggered by partial unfolding or environmental changes such as pH shifts.
• Supersaturation and condensate metastability are critical factors that determine whether amyloid fibril formation proceeds or is prevented under proteostasis.
• Key proteins involved include amyloid-beta, apomyoglobin fragments, apolipoproteins, and PMEL, which serve as models for studying fibril assembly.
• Research methods such as Congo red binding, fluorescence microscopy, and proteomics are essential to characterize fibril formation and its regulation.
Description
Amyloid fibril formation (GO:1990000) is a biological process defined as the generation of amyloid fibrils, which are insoluble fibrous protein aggregates exhibiting beta sheet structure, from proteins. This process is not limited to pathological states; it also plays functional roles in organisms, such as the formation of PMEL amyloid fibrils that are essential for melanin deposition in pigmentation. Understanding the molecular mechanisms of amyloid fibril formation is crucial because it underlies a wide range of human disorders, including neurodegenerative diseases and systemic amyloidoses. The process involves the conversion of soluble proteins into highly ordered, beta-sheet-rich fibrils through a nucleation-dependent polymerization mechanism. Recent studies have highlighted the importance of protein supersaturation and condensate metastability in regulating amyloid fibril formation, providing new insights into proteostasis. This article synthesizes current knowledge on the mechanisms, key genes, and research methods associated with GO:1990000, based on authoritative QuickGO data and verified PubMed literature.
amyloid fibril formation At A Glance
| GO ID | GO:1990000 |
|---|---|
| GO term | amyloid fibril formation |
| Ontology | biological_process |
| Synonym | amyloid fibril assembly, amyloid structure assembly, amyloid structure formation |
| Major function | Generation of insoluble fibrous protein aggregates with beta sheet structure from proteins |
| Related processes | Protein aggregation, proteostasis, neurodegeneration |
| Key triggers | Partial unfolding, pH changes, supersaturation, condensate metastability |
| Disease relevance | Alzheimer's disease, atherosclerosis, pigmentation disorders |
What Is GO:1990000?
Amyloid fibril formation (GO:1990000) is the biological process by which proteins assemble into amyloid fibrils, which are insoluble, fibrous aggregates characterized by a cross-beta sheet structure. This definition, based on the Gene Ontology, encompasses the generation of these fibrils from precursor proteins, often through partial unfolding or exposure of aggregation-prone segments.
Why Is amyloid fibril formation Important in Cell Biology?
Amyloid fibril formation is critically important because it represents a fundamental mechanism linking protein misfolding to both normal physiology and disease. In physiological contexts, amyloid fibrils serve essential functions, such as in melanin synthesis where PMEL amyloid fibrils act as scaffolds. Pathologically, the same process contributes to the pathogenesis of numerous disorders, including Alzheimer's disease, where beta-amyloid fibrils are a hallmark, and atherosclerosis, where apolipoproteins form amyloid deposits. Understanding the regulation of amyloid fibril formation, including factors like supersaturation and condensate metastability, is therefore vital for developing therapeutic strategies.
• Amyloid fibril formation is a hallmark of neurodegenerative diseases such as Alzheimer's disease, where beta-amyloid fibrils accumulate in the brain.
• The process is involved in atherosclerosis through the formation of amyloid fibrils from apolipoproteins, contributing to plaque stability and cardiovascular risk.
• Physiological amyloid fibril formation is essential for pigmentation, as PMEL fibrils template melanin deposition.
• Supersaturation of proteins is a critical factor that determines the propensity for amyloid fibril formation and is linked to proteostasis.
• Condensate metastability can either promote or inhibit amyloid fibril formation, revealing dual roles in cellular regulation.
• Exposure of aggregation-prone segments, often through partial unfolding, is a prerequisite for amyloid fibril formation.
• pH changes can trigger amyloid fibril formation, as shown for apomyoglobin fragment 1-29.
• Congo red binding is a classic method to detect amyloid fibrils and provides insights into their structure.
• A new mechanism of amyloid fibril formation has been proposed, expanding the understanding of fibril assembly pathways.
• Research on amyloid fibril formation informs drug development targeting protein aggregation in various diseases.
What Happens During amyloid fibril formation?
Initiation and Nucleation
In simple terms: The process starts when proteins partially unfold and expose sticky regions that can stick together.
Amyloid fibril formation typically begins with the partial unfolding or destabilization of a native protein, leading to the exposure of aggregation-prone segments. This exposure can be triggered by environmental factors such as pH changes, as demonstrated for apomyoglobin fragment 1-29, where acidic pH induces fibril formation. The initial step involves the formation of a nucleus or seed, a thermodynamically unfavorable process that is rate-limiting. Recent studies suggest that supersaturation, the ratio of protein concentration to its solubility, is a critical factor that drives nucleation and subsequent fibril growth.
Elongation and Fibril Growth
In simple terms: Once a seed forms, more proteins attach to it, building long fibers.
Following nucleation, fibril elongation proceeds rapidly as monomeric proteins add to the growing fibril ends. This step is driven by the beta-sheet-rich structure of the fibril, which provides a template for further protein recruitment. The process can be influenced by the metastability of protein condensates, which may serve as reservoirs for fibril-forming proteins. For example, PMEL amyloid fibrils elongate in a controlled manner to form the structural core of melanosomes.
Condensate Metastability and Regulation
In simple terms: Tiny droplets of protein can either help or hinder fiber formation depending on their stability.
Liquid-liquid phase separation can produce protein condensates that modulate amyloid fibril formation. The metastability of these condensates, meaning their tendency to dissolve or transition to a solid state, determines whether they promote or inhibit fibril formation. This dual role reconciles seemingly contradictory observations and highlights the complexity of cellular regulation. Supersaturation also plays a key role in maintaining proteostasis by preventing spontaneous fibril formation under normal conditions.
Fibril Maturation and Disaggregation
In simple terms: Fibers can become more stable over time, but some can also be broken down.
Mature amyloid fibrils are highly stable and resistant to degradation, but they can undergo disaggregation under certain conditions. For instance, fragment 1-29 of apomyoglobin forms fibrils that can be disaggregated by pH shifts, indicating reversibility. The balance between fibril formation and disaggregation is critical for cellular proteostasis and is influenced by chaperones and other regulatory factors.
Key Genes Involved in GO:1990000 amyloid fibril formation
The following genes and proteins are key players in amyloid fibril formation, as supported by the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| APP | Precursor of amyloid-beta, which forms fibrils in Alzheimer's disease | Central to Alzheimer's disease research and fibril structure studies |
| APOA1 | Apolipoprotein involved in lipid transport; forms amyloid fibrils in atherosclerosis | Link between lipid metabolism and amyloid formation |
| APOA2 | Apolipoprotein that can form amyloid fibrils | Implicated in atherosclerosis and amyloidosis |
| PMEL | Forms functional amyloid fibrils in melanosomes for pigmentation | Model for physiological amyloid formation |
| MB | Myoglobin; its fragment 1-29 forms amyloid fibrils in vitro | Model for pH-dependent fibrillogenesis |
| B2M | Beta-2-microglobulin forms amyloid fibrils in dialysis-related amyloidosis | Model for amyloid formation in systemic amyloidoses |
| TTR | Transthyretin forms amyloid fibrils in familial amyloid polyneuropathy | Target for therapeutic development |
| LYZ | Lysozyme variants form amyloid fibrils in hereditary systemic amyloidosis | Model for protein misfolding diseases |
| SNCA | Alpha-synuclein forms amyloid fibrils in Parkinson's disease | Key target in neurodegeneration research |
| HTT | Huntingtin with polyglutamine expansions forms amyloid fibrils | Relevant to Huntington's disease |
| IAPP | Islet amyloid polypeptide forms fibrils in type 2 diabetes | Link between amyloid and metabolic disease |
| PRNP | Prion protein forms amyloid fibrils in prion diseases | Model for infectious protein misfolding |
| SOD1 | Superoxide dismutase 1 mutants form amyloid fibrils in ALS | Implicated in amyotrophic lateral sclerosis |
| FUS | FUS protein forms amyloid fibrils in ALS and FTLD | RNA-binding protein with aggregation propensity |
| TARDBP | TDP-43 forms amyloid fibrils in ALS and FTLD | Major component of pathological inclusions |
| CRYAB | Alpha-crystallin B chain; chaperone that modulates amyloid formation | Regulates fibril formation and proteostasis |
| HSPA1A | Hsp70 chaperone that inhibits amyloid fibril formation | Key regulator of proteostasis |
How Is amyloid fibril formation Regulated?
Amyloid fibril formation is regulated at multiple levels to maintain proteostasis. Supersaturation, the ratio of protein concentration to solubility, acts as a critical determinant; when supersaturation is high, proteins are poised to aggregate, but under normal conditions, the cell maintains supersaturation below the threshold for spontaneous nucleation. Molecular chaperones, such as Hsp70 and alpha-crystallin, inhibit fibril formation by binding to aggregation-prone segments and preventing their assembly. Additionally, the metastability of protein condensates can either promote or inhibit fibril formation, depending on their material properties and the cellular context. These regulatory mechanisms ensure that amyloid fibril formation occurs only when needed, such as in PMEL for pigmentation, and is prevented in other contexts.
amyloid fibril formation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| APP | Alzheimer's disease | Knockout or knock-in of APP mutations in cell lines; fibril formation assays |
| APOA1 | Atherosclerosis | Overexpression of APOA1 in hepatocytes; amyloid fibril detection |
| PMEL | Pigmentation disorders | Knockout of PMEL in melanocytes; rescue with wild-type or mutant PMEL |
| TTR | Familial amyloid polyneuropathy | Point mutations in TTR (e.g., V30M) in HEK293 cells; fibril formation under acidic pH |
| SNCA | Parkinson's disease | Overexpression of alpha-synuclein in neuronal cells; fibril seeding assays |
Amyloid Fibril Formation in Neurodegenerative Diseases
Amyloid fibril formation is a central pathological feature of several neurodegenerative diseases. In Alzheimer's disease, the beta-amyloid peptide aggregates into fibrils that deposit in senile plaques, contributing to neuronal dysfunction and death. The structure of these fibrils has been studied using Congo red binding, which reveals a cross-beta sheet conformation. Similarly, in Parkinson's disease, alpha-synuclein forms amyloid fibrils known as Lewy bodies, and in amyotrophic lateral sclerosis, TDP-43 and FUS aggregate into fibrillar inclusions. Understanding the molecular mechanisms of fibril formation is essential for developing therapies that target these aggregates.
Amyloid Fibril Formation in Cardiovascular Disease
Atherosclerosis involves the deposition of apolipoproteins, such as APOA1 and APOA2, as amyloid fibrils within arterial walls. These fibrils contribute to plaque formation and stability, and their presence is associated with increased cardiovascular risk. The process of amyloid fibril formation in atherosclerosis is driven by factors similar to those in neurodegeneration, including protein supersaturation and exposure of aggregation-prone segments. Research into apolipoprotein fibrillogenesis provides insights into the link between lipid metabolism and amyloid diseases.
Physiological Amyloid Fibril Formation in Pigmentation
Not all amyloid fibrils are pathological; PMEL forms functional amyloid fibrils in melanosomes that serve as scaffolds for melanin deposition. This process is essential for normal pigmentation, and defects in PMEL fibril formation lead to pigmentation disorders. The study of PMEL amyloid fibrils has provided valuable insights into the structural and functional aspects of amyloid formation, demonstrating that the same process can be beneficial in one context and detrimental in another.
From amyloid fibril formation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does knockout of a candidate gene affect amyloid fibril formation? | CRISPR knockout cell lines (e.g., HEK293, SH-SY5Y) followed by fibril formation assays |
| Does a specific point mutation alter fibril formation kinetics? | Point mutation knock-in cell lines (e.g., APP Swedish mutation) |
| Can a tagged protein be used to track fibril formation in live cells? | Knock-in of fluorescent tags (e.g., GFP) at the endogenous locus |
| Does overexpression of a chaperone inhibit fibril formation? | Overexpression cell lines for HSPA1A or CRYAB |
| What is the effect of supersaturation on fibril nucleation? | Cell lines with inducible expression of amyloidogenic proteins |
| How do condensates regulate fibril formation? | Knock-in of phase separation reporters; live-cell imaging |
How to Study the amyloid fibril formation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Congo red binding | Presence of amyloid fibrils with cross-beta structure | Detection of amyloid deposits in tissues and in vitro |
| Thioflavin T fluorescence | Fibril formation kinetics | Real-time monitoring of fibril assembly |
| Mass spectrometry | Protein composition of amyloid aggregates | Identification of amyloid components in disease |
| Circular dichroism | Secondary structure changes (beta-sheet content) | Monitoring conformational transitions during fibril formation |
| Dynamic light scattering | Size distribution of aggregates | Characterizing oligomers and fibrils |
| Fluorescence microscopy | Localization and dynamics of tagged proteins | Live-cell imaging of fibril formation |
| Surface plasmon resonance | Binding kinetics of proteins to fibrils | Quantifying elongation rates |
| Proteomics | Global protein changes during fibril formation | Identifying novel regulators and biomarkers |
Congo Red Binding and Fluorescence Microscopy
Congo red binding is a classic method to detect amyloid fibrils, as it intercalates into the cross-beta sheet structure and exhibits a characteristic green birefringence under polarized light. This technique has been used to study beta-amyloid fibril formation and structure, providing insights into the arrangement of beta sheets. Fluorescence microscopy with amyloid-specific dyes, such as thioflavin T, allows real-time monitoring of fibril formation in vitro and in cells.
Proteomics and Mass Spectrometry
Proteomic approaches, including mass spectrometry, are used to identify proteins that co-aggregate with amyloid fibrils and to characterize post-translational modifications that influence fibril formation. These methods can reveal the composition of amyloid deposits in tissues and body fluids, aiding in biomarker discovery.
Biophysical Techniques for Fibril Kinetics
Techniques such as circular dichroism, dynamic light scattering, and surface plasmon resonance are employed to monitor the conformational changes and kinetics of amyloid fibril formation. These methods provide quantitative data on nucleation, elongation, and disaggregation rates, which are essential for understanding the effects of mutations or environmental factors.
Cell-Based Assays for Fibril Formation
Cell-based assays using fluorescently tagged amyloidogenic proteins allow the visualization of fibril formation in living cells. For example, PMEL fibrils can be tracked using fluorescent tags in melanocytes. These assays are valuable for studying the regulation of fibril formation by chaperones, condensates, and other cellular factors.
How CRISPR Can Be Used to Study GO:1990000 amyloid fibril formation
Knockout
CRISPR knockout is used to delete genes encoding amyloidogenic proteins or their regulators to determine their role in fibril formation. For example, knocking out PMEL in melanocytes abolishes functional amyloid fibrils and impairs pigmentation, demonstrating its essential role. Similarly, knockout of chaperones like HSPA1A can enhance fibril formation, confirming their protective function.
Point Mutation
Point mutations can be introduced using CRISPR to model disease-associated variants that alter fibril formation. For instance, the Swedish mutation in APP (KM670/671NL) increases beta-amyloid production and fibril formation, and can be knocked into cell lines to study Alzheimer's disease mechanisms. Point mutations in TTR, such as V30M, are associated with familial amyloid polyneuropathy and can be modeled in vitro.
Knock-in
Knock-in of fluorescent tags or reporter genes allows real-time tracking of amyloid fibril formation in live cells. For example, knocking in a GFP tag at the PMEL locus enables visualization of fibril assembly in melanosomes. Knock-in of disease-associated mutations, such as those in SNCA, provides more physiologically relevant models than overexpression.
Overexpression
Overexpression of amyloidogenic proteins or their mutants is a common approach to induce fibril formation in cell models. Overexpression of alpha-synuclein in neuronal cells leads to the formation of amyloid fibrils and cellular toxicity, mimicking Parkinson's disease. Overexpression of apolipoproteins in hepatocytes can induce amyloid fibril formation relevant to atherosclerosis.
How EDITGENE Supports amyloid fibril formation Research
Researchers studying amyloid fibril formation-related genes often need to determine whether a candidate gene is causally involved in fibril assembly, how specific mutations affect aggregation kinetics, or whether a protein of interest localizes to amyloid deposits. EDITGENE provides a comprehensive suite of CRISPR-based services to address these questions, from generating knockout cell lines to creating precise point mutations and knock-in reporters, enabling mechanistic studies of GO:1990000.
Contact EDITGENE today to design your custom CRISPR model for amyloid fibril formation research.
Frequently Asked Questions About amyloid fibril formation
What is amyloid fibril formation?
Amyloid fibril formation (GO:1990000) is the biological process by which proteins assemble into insoluble fibrous aggregates with a cross-beta sheet structure, known as amyloid fibrils.
What genes are involved in amyloid fibril formation?
Key genes include APP, APOA1, PMEL, TTR, SNCA, and many others that encode amyloidogenic proteins or their regulators.
How does amyloid fibril formation relate to Alzheimer's disease?
In Alzheimer's disease, beta-amyloid peptides form amyloid fibrils that deposit in the brain, contributing to neurodegeneration.
What is the role of supersaturation in amyloid fibril formation?
Supersaturation, the ratio of protein concentration to solubility, is a critical factor that determines the propensity for amyloid fibril formation and is linked to proteostasis.
Can amyloid fibril formation be beneficial?
Yes, PMEL forms functional amyloid fibrils in melanosomes that are essential for pigmentation.
What methods are used to study amyloid fibril formation?
Common methods include Congo red binding, thioflavin T fluorescence, circular dichroism, and fluorescence microscopy.
How do condensates regulate amyloid fibril formation?
Condensate metastability can either promote or inhibit fibril formation, depending on their material properties and cellular context.
What is the role of pH in amyloid fibril formation?
pH changes can trigger fibril formation by altering protein stability and exposing aggregation-prone segments, as shown for apomyoglobin fragment 1-29.
Which diseases are associated with amyloid fibril formation?
Diseases include Alzheimer's disease, atherosclerosis, Parkinson's disease, and familial amyloid polyneuropathy.
How can CRISPR be used to study amyloid fibril formation?
CRISPR can create knockout, point mutation, knock-in, and overexpression models to dissect the role of specific genes in fibril formation.
Conclusion
Amyloid fibril formation (GO:1990000) is a fundamental biological process with profound implications for both normal physiology and disease. The generation of amyloid fibrils from soluble proteins involves complex mechanisms regulated by supersaturation, condensate metastability, and chaperones. Key genes such as APP, PMEL, and APOA1 serve as models for understanding fibril assembly in neurodegeneration, pigmentation, and cardiovascular disease. Advances in CRISPR-based models and biophysical methods continue to unravel the molecular details of this process, offering hope for therapeutic interventions. EDITGENE's comprehensive services empower researchers to investigate amyloid fibril formation with precision and efficiency.
References
- 1. Galzitskaya O. 2019. New Mechanism of Amyloid Fibril Formation.. Curr Protein Pept Sci 20(6):630-640 PMID: 30686252
- 2. Bissig C et al.. 2016. PMEL Amyloid Fibril Formation: The Bright Steps of Pigmentation.. Int J Mol Sci 17(9) PMID: 27589732
- 3. Goto Y et al.. 2024. Supersaturation, a Critical Factor Underlying Proteostasis of Amyloid Fibril Formation.. J Mol Biol 436(14):168475 PMID: 38311232
- 4. Teoh CL et al.. 2011. Apolipoproteins and amyloid fibril formation in atherosclerosis.. Protein Cell 2(2):116-27 PMID: 21400045
- 5. Das T et al.. 2025. Tunable metastability of condensates reconciles their dual roles in amyloid fibril formation.. Mol Cell 85(11):2230-2245.e7 PMID: 40441157
- 6. Pramanik S et al.. 2018. Exposure of Aggregation-Prone Segments is the Requirement for Amyloid Fibril Formation.. Curr Protein Pept Sci 19(10):1024-1035 PMID: 29779477
- 7. Picotti P et al.. 2007. Amyloid fibril formation and disaggregation of fragment 1-29 of apomyoglobin: insights into the effect of pH on protein fibrillogenesis.. J Mol Biol 367(5):1237-45 PMID: 17320902
- 8. Inouye H et al.. 2005. Alzheimer's beta-amyloid: insights into fibril formation and structure from Congo red binding.. Subcell Biochem 38:203-24 PMID: 15709480
